Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2011-03-01
2011-03-01
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S186100, C424S185100, C424S085100, C530S300000, C530S402000, C530S403000, C514S001000, C514S002600, C514S885000
Reexamination Certificate
active
07897152
ABSTRACT:
The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4704362 (1987-11-01), Itakura et al.
patent: 5989552 (1999-11-01), McKenzie et al.
patent: 6001649 (1999-12-01), Caput et al.
patent: 6562347 (2003-05-01), Kwak et al.
patent: 0706799 (1996-04-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 97/35008 (1997-09-01), None
patent: WO 98/01564 (1998-01-01), None
patent: WO 98/07833 (1998-02-01), None
patent: WO 99/46392 (1999-09-01), None
patent: WO 9946392 (1999-09-01), None
patent: WO 00/78334 (2000-12-01), None
Moore et. al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV (1996) Science, vol. 274, pp. 1739-1744.
Lalani et. al. Evasion and exploitation of chemokines by viruses (1999) Cytokine and Growth Factor Reviews, vol. 10 , pp. 219-233.
Murphy, P. Viral exploitation and subversion of the immune system through chemokine mimicry (2001) Nature Immunology, 2(2), pp. 116-122.
Biragyn, A. et. al. Chemokine receptor-mediated delivery directs self-tumor antigen effectively into the class II processing pathway in vitor and induces protective immunity in vivo (2004) Blood, 104(7) pp. 1961-1969.
Biragyn, A. et. al. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions (1999) Immunological Reviews, vol. 170, pp. 115-126.
Biragyn, A. et. al. Genetic fusion of chemokine to a self (1999) Nature Biotechnology, vol. 17, p. 253-258.
Dairaghi et al. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. The Journal of Biological Chemistry, Jul. 30, 1999, vol. 274, No. 31, pp. 21569-21574.
Romero et al. Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine 2002, vol. 20, pp. A2-A7.
Choudhury et al. Clinical Results of Vaccine Therapy for Cancer. Advances in Cancer Research 2006, vol. 95, pp. 147-202.
Dermime et al. Vaccine and antibody-directed T cell tumour immunotherapy. Biochimica et Biophysica Acta 2004, vol. 1704, pp. 11-35.
Tassone et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005, vol. 106, pp. 713-716.
Ferrone et al. A clinically relevant mouse model of human multiple myeloma? Blood 2005, vol. 106, pp. 388-389.
Agrawal et al. Cell-cycle kinetics and VSV-G pseudotyped retrovirus mediated gene transfer in blood-derived CD34+ cells.Exp. Hematol. 24:738-747 (1996).
Alvarez et al. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients.Hum. Gene Ther. 8:229-242 (1997).
Amon, ed. Chapter 6: The choice of carrier.Synthetic VaccinesI:83-92 CRC Press, Inc., Boca Raton, FL (1987).
Baggiolini et al. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines.Adv. Immunol. 55:97-179 (1994).
Barbas et al. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. PNAS 89:4457-4461 (1992).
Belyakov et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.J Virol. 72(10):8264-8272 (1998).
Belyakov et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.Proc Natl Acad Sci USA. 95(4):1709-1714 (1998).
Ben-Baruch et al. The differential ability of IL-8 and neutrophil-activating peptide-2 to induce attenuation of chemotaxis is mediated by their divergent capabilities to phosphorylate CXCR2 (IL-8 receptor B).J Immunol158(12):5927-5933 (1997).
Bergman et al. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin.Eur. J. Immunol. 7:413-417 (1977).
Biragyn et al. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.Immunological Review170:115-126 (1999).
Biragyn et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.Nature Biotechnology17:253-258 (1999).
Blasi et al. Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus.Nature318:667-670 (1985).
Bonecchi et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.J Exp Med187(1):129-134 (1998).
Brake et al. α-factor-directed synthesis and secretion of mature foreign proteins inSaccharomyces cerevisiae. PNAS81:4642-4646 (1984).
Bridges. Participation of the humoral immune system in the myeloma-specific transplantation resistance.J Immunol121(2):479-483 (1978).
Buchner et al. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.Analytical Biochem. 205:263-270 (1992).
Butcher. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity.Cell67:1033-1038 (1991).
Bystryn. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens.Annals New York Academy of Sciences690:190-203 (1993).
Campbell et al. Development of a new therapeutic approach to B cell malignancy: the induction of immunity by the host against cell surface receptor on the tumor.Int Rev Immuno4:251-270 (1989).
Campbell et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.J Immunol145(3):1029-1036 (1998).
Campbell et al. Idiotype vaccination against murine B cell lymphoma humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.J Immunol139(8):2825-2833 (1987).
Crystal et al. Phase I study of direct administration of a replication deficient adenovirus vector containing theE. colicytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine.Human Gene Therapy8:985-1001 (1997).
Daley et al. Idiotype-specific transplantation resistance to MOPC-315: abrogaton by post-immunization thymectomy.J Immunol120(5):1620-1624 (1978).
Damon et al. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog.Proc Nat Acad Sci USA. 95(11):6403-6407 (1998).
Davis et al. DNA-based immunization against hepatitis B surface antigen (HBsAg) in mormal and HbsAg-transgenic mice.Vaccine15(8):849-852 (1997).
Dieu et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.J Exp Med. 188(2):373-386 (1998).
Dilloo et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity.Nature Medicine2(10):1090-1095 (1998).
Dyke et al. Idiotypic vaccine against B-cell lymphoma leads to dormant tumour.Cell Immunol132:70-83 (1991).
Emini et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.Nature355:728-730 (1992).
Endres et al. The Kaposi's sarcoma-related herpes virus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8.J Exp Med. 189(12):1993-1998 (1999).
Fairbrother et al. Chapter 3—Three-dimensional structures of the chemokine family.Chemoattractant Ligands and Their Receptors. Horuk, ed. CRC Press, pp.
Biragyn Arya
Kwak Larry W.
Humphrey Louise
Klarquist & Sparkman, LLP
Lucas Zachariah
The United States of America as represented by the Secretary of
LandOfFree
Viral chemokine-antigen fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral chemokine-antigen fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral chemokine-antigen fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734323